Pharmasol Gmbh

Pharmatec International S.r.l.

Rainer Helmut M&uuml;ller

Lawrence John Penkler

Carsten Olbrich

Karsten M&auml;der

Stephan Anton Runge

Sylvia Wissing

Vittorino Ravelli

The invention relates to agents with UV radiation-absorbing and/or reflecting action comprising solid, polymorphic, crystal-line or partially crystalline lipid and/or polymer particles, for application to the skin, mucous membranes, scalp, and hair for protection against health-damaging UV radiation and for strengthening the natural skin barrier.

UV radiation reflecting or absorbing agents, protecting against harmful UV radiation and reinforcing the natural skin barrier

The invention relates to particulate active ingredient vehicles which are in the solid aggregate state at room temperature (20&deg; C.) and consist of a pure lipid-drug conjugate (LDC) or a mixture of several LDCs as particle matrix, the bond in the LDC being effected by covalent bonding, electrostatic interactions, dipole moments, dispersion forces, ion interactions, hydrogen bridges and/or hydrophobic interactions.

Lipid matrix-drug conjugates particle for controlled release of active ingredient

The invention relates to solid, particulate lipid-based excipients which are loaded with cyclosporine. Said excipients have improved biopharmaceutical properties for cyclosporines in vivo, are of a better quality (in terms of fineness, homogeneity of the particles, inclusion of the medicament) and are more physically stable in the particulate formulation (no aggregation or gel formation). The invention also relates to a therapeutic treatment with cyclosporine formulations which produce an average blood level concentration in the steady state range of 300 ng/ml to over 1000 ng/ml, preferably over 800 ng/ml, especially up to 900 ng/ml, preferably 400 ng/ml to 800 ng/ml in the absence of high initial blood level concentrations essentially over 1500 ng/ml, especially over 1200 ng/ml. This blood level concentration is preferably maintained for an extended period of at least 5 hours, preferably at least 7 hours.

Pharmaceutical cyclosporin formulation with improved biopharmaceutical properties, improved physical quality and greater stability, and method for producing said formulation

Growing community of inventors

Berlin, Germany

Rainer Helmut Müller

Growing community of inventors

Berlin, Germany

Rainer Helmut M&uuml;ller

Rainer Helmut Müller